In patients receiving tirzepatide, the downstream activation of GLP-1 and GIP receptor-mediated molecular pathways, especially in those with chronic pancreatitis, could increase the risk of developing pancreatic cancer [41]
G.DeguH
collected data from seven cardiovascular outcome trials with 56,004 patients with T2DM and a median followup ranging from 1.3 to 5.4 years, with no significant difference compared to placebo for acute pancreatitis (OR: 1.05, 0.781.40, p = 0.76) or pancreatic cancer (OR: 1.12, 0.771.63, p = 0.56) [19]
Understanding why those timelines exist gives you the knowledge to protect your investment
Systemic stress response after laparoscopic and open gastric bypass
Shis group developed a biomimetic nanoparticles by modifying angiopep-2 to the surface of red blood cell membranes to camouflage polymer which was pH-sensitive and coload with anti-cancer drug DOX and BBB regulator lexiscan (Fig